



(11) **EP 4 209 504 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

(15) Correction information:
Corrected version no 1 (W1 A1)
Corrections, see
Bibliography INID code(s) 54
Abstract

(51) International Patent Classification (IPC):
C07K 14/775 ^(2006.01) **C07K 1/14** ^(2006.01)
C07K 1/30 ^(2006.01) **C07K 1/34** ^(2006.01)
C07K 1/36 ^(2006.01) **A61K 38/17** ^(2006.01)
A61K 31/685 ^(2006.01) **A61K 31/688** ^(2006.01)
A61P 3/06 ^(2006.01)

(48) Corrigendum issued on:
14.02.2024 Bulletin 2024/07

(52) Cooperative Patent Classification (CPC):
C07K 14/775; A61P 1/16; A61P 3/06; A61P 9/10;
A61P 29/00; A61P 39/02; A61K 38/00; A61K 38/17

(43) Date of publication:
12.07.2023 Bulletin 2023/28

(21) Application number: **22213998.2**

(22) Date of filing: **05.06.2014**

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

• **WARREN, Gary, Lee**
Bourbonnais, IL 60944 (US)

(30) Priority: **05.06.2013 US 201361831304 P**

(74) Representative: **Carpmaels & Ransford LLP**
One Southampton Row
London WC1B 5HA (GB)

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
14808213.4 / 3 004 160

Remarks:

- This application was filed on 15-12-2022 as a
divisional application to the application mentioned
under INID code 62.
- Claims filed after the date of filing of the application
/ after the date of receipt of the divisional application
(Rule 68(4) EPC).

(71) Applicant: **CSL Limited**
Melbourne VIC 3000 (AU)

(72) Inventors:
• **VUCICA, Yvonne**
3006 Bern (CH)

(54) **PROCESS FOR PREPARING APOLIPOPROTEIN A-I (APO A-I)**

(57) The present invention relates to processes of
obtaining Apo A-I from an Apo A-I containing protein frac-
tion (A), comprising suspending the Apo A-I containing
protein fraction (A) in a buffer solution (B), removing im-
purities from the suspension while keeping the Apo A-I
proteins solubilized, followed by precipitating Apo A-I

from the suspension and collecting the Apo A-I precipi-
tate. Apo A-I obtained by such processes, reconstituted
HDL obtained from such Apo A-I, and pharmaceutical
compositions comprising such Apo A-I and/or reconsti-
tuted HDL also are provided.

EP 4 209 504 A8